Literature DB >> 17635976

The clock keeps ticking for intravenous methylprednisolone.

Florian Then Bergh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17635976      PMCID： PMC2117721          DOI： 10.1136/jnnp.2006.109272

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  6 in total

1.  Chronotherapy using corticosteroids for multiple sclerosis relapses.

Authors:  Lea Glass-Marmor; Tamar Paperna; Yaara Ben-Yosef; Ariel Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10-20       Impact factor: 10.154

2.  Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

Authors:  R Zivadinov; R A Rudick; R De Masi; D Nasuelli; M Ukmar; R S Pozzi-Mucelli; A Grop; G Cazzato; M Zorzon
Journal:  Neurology       Date:  2001-10-09       Impact factor: 9.910

3.  Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial.

Authors:  Jeremy Chataway; Bernadette Porter; Afsane Riazi; Dominic Heaney; Hilary Watt; Jeremy Hobart; Alan Thompson
Journal:  Lancet Neurol       Date:  2006-07       Impact factor: 44.182

Review 4.  Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.

Authors:  G Filippini; F Brusaferri; W A Sibley; A Citterio; G Ciucci; R Midgard; L Candelise
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 5.  The chronobiology of human cytokine production.

Authors:  N Petrovsky; L C Harrison
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

6.  Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.

Authors:  Florian Then Bergh; Tania Kümpfel; Erina Schumann; Ulrike Held; Michaela Schwan; Mirjana Blazevic; Axel Wismüller; Florian Holsboer; Alexander Yassouridis; Manfred Uhr; Frank Weber; Martin Daumer; Claudia Trenkwalder; Dorothee P Auer
Journal:  BMC Neurol       Date:  2006-05-23       Impact factor: 2.474
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.